The DOI matches its Crossref record, with a small difference in title or year; 1,376 of the 1,396 references it cites were found in a registry or an index.
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Open accessAbstract
AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lifestyle modification is not only effective for supporting moderate weight loss (5% to 10% of weight), but it also has favorable effects on multiple metabolic risk factors, even independent of weight loss.8–11”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Components should include dietary changes to promote a calorie deficit of 500 to 750 kcal/day, ≥150 minutes per week of moderately vigorous aerobic activity, and ≥14 months of behavioral therapy, including self-monitoring of dietary intake, physical activity, and weight, and guided problem solving.9,10”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The AHA/ACC and several societies recommend intensive, multicomponent behavioral weight loss interventions led by clinicians having the ability to successfully initiate weight loss counseling.9–11”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, habitual physical activity, including activities that reduce sedentary time, aerobic physical activity, and resistance training, are associated with improvements in several CKM risk factors (HbA1c, waist circumference, fat percentage, BP) and mortality.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A heart-healthy diet and regular physical activity remain the cornerstones of therapy in patients with T2D and ASCVD, with demonstrated benefits for CKM risk profiles.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Small lifestyle intervention trials suggest weight loss efficacy and safety in HFrEF,8–10”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among patients with kidney failure (end-stage kidney disease) receiving dialysis, CVD rates are high and the leading cause of death, with unique CVD phenotypes.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Screening caregivers of youth populations for SDOH identifies childhood exposures to social factors that can influence CKM health across the life course.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Additionally, comorbid conditions such as CVD and obstructive sleep apnea (OSA) do not interfere with the success of weight loss in several studies.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among patients who have undergone MBS and have regained a significant amount of weight (≥25% or more of total lost weight), GLP-1–based therapies can be useful in promoting weight loss and management of comorbidities.9–13”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) comprise 90% of all procedures.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The oral formulation appears slightly less efficacious than the subcutaneous version for facilitating weight loss.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This translated into a number needed to treat of 49 over 3 years to prevent 1 HF event.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although other measures of atherosclerosis (eg, ankle brachial index, carotid intima media thickness) have shown utility in risk assessment,9–11 studies have been limited in demonstrating their utility for guiding clinical care.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the only dedicated GLP-1 RA trial of patients with diabetes and albuminuric CKD (FLOW), semaglutide demonstrated a significant reduction in HF events in the overall sample (HR, 0.74 [95% CI, 0.58–0.94]) with similar reduction in incident HF among those without baseline HF (HR, 0.68 [95% CI, 0.50–0.91]).8,9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Nonrandomized reports across a spectrum of HF (ambulatory patients with chronic HF, a new HF diagnosis, and individuals with a recent hospitalization) and a variety of ages do not support harm with metformin therapy, though metformin is contraindicated in decompensated HF.9,30”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“though metformin is contraindicated in decompensated HF.9,30”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Initiation of SGLT2i is efficacious in reducing risk of the outcomes of cardiovascular mortality, HF hospitalization, and decline in eGFR for patients with stage 4 CKM with CKD (GFR >20 mL/min/1.73 m2) and HFrEF, particularly for those with albuminuria.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“but data are more sparse in patients with severely decreased kidney disease (stage G4 CKD), and the presence/absence of albuminuria is understudied in HF trials.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SGLT2i initiation have demonstrated efficacy among patients with eGFR >20 mL/min/1.73 m2 and HFmrEF/HFpEF in reducing composite cardiovascular mortality and HF hospitalizations, but data are more sparse in patients with severely decreased kidney disease (stage G4 CKD), and the presence/absence of albuminuria is understudied in HF trials.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a substudy of the randomized, open-label, parallel-group, Phase III SURPASS-3 trial, tirzepatide, a GLP-1/GIP receptor agonist approved for treatment of T2D, compared to insulin degludec, significantly reduced liver fat content among persons with T2D.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“GLP-1–based therapy can be an effective adjunctive treatment to achieve weight loss goals in MASLD, with additional favorable effects on liver histology as discussed below.8,9,42”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Meta-analyses and cohort studies have found that women with CKD are at increased risk of APOs.9–11,39”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
Self-citationRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.
Haïssaguerre, M., Jaïs, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Mouroux, A. L., Métayer, P. L., & Clémenty, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809033391003 · Cited by 8,040
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y.-H., McAnulty, J. H., Zheng, Z.-J., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005119 · Cited by 4,506
Self-citation(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Self-citationA comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,289
Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,244
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Hannun, A. Y., Rajpurkar, P., Haghpanahi, M., Tison, G. H., Bourn, C., Turakhia, M. P., & Ng, A. Y. (2019) · Nature Medicine · doi:10.1038/s41591-018-0268-3 · Cited by 3,148
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationCalkins, H. G., Hindricks, G., Cappato, R., Kim, Y., Saad, E., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, A. J., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.05.012 · Cited by 2,794
Self-citationCatheter Ablation for Atrial Fibrillation with Heart Failure
MARROUCHE, N. F., Brachmann, J., Andresen, D., Siebels, J., Boersma, L. V. A., Jordaens, L. J. L. M., Merkely, B. P., Pokushalov, E., Sanders, P., Proff, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1707855 · Cited by 2,514
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Thyroid hormone and the cardiovascular system.
Klein, I., & Ojamaa, K. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440707 · Cited by 2,300
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cífková, R., De Bonis, M., Iung, B., Johnson, M. R., Kintscher, U., Kranke, P., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy340 · Cited by 2,292
January, C. T., Wann, L. S., Calkins, H. G., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,252
Self-citationHolmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., Mullin, C. M., & Sick, P. B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61343-x · Cited by 2,242
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation
Kirchhof, P. F., Camm, A. J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., Fetsch, T., Gelder, I. C. V., Haase, D., Haegeli, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019422 · Cited by 2,227
Cryptogenic stroke and underlying atrial fibrillation
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313600 · Cited by 2,161
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 2,110
Subclinical atrial fibrillation and the risk of stroke
Healey, J. S., Connolly, S. J., Gold, M. R., Israel, C. W., Van Gelder, I. C., Capucci, A., Lau, C. P., Fain, E., Yang, S., Bailleul, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105575 · Cited by 2,100
Physician advice for smoking cessation
Stead, L. F., Buitrago, D., Preciado, N., Sanchez, G., Hartmann-Boyce, J., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000165.pub4 · Cited by 1,955
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., Balasubramanian, V., Russo, A. M., Rajmane, A., Cheung, L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901183 · Cited by 1,917
Self-citation2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Self-citationHolmes, D. R., Kar, S., Price, M. J., Whisenant, B. K., Sievert, H., Doshi, S. K., Huber, K., & Reddy, V. Y. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.029 · Cited by 1,874
Sweeney, M. O., Hellkamp, A. S., Ellenbogen, K. A., Greenspon, A. J., Freedman, R. A., Lee, K. L., & Lamas, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000072769.17295.b1 · Cited by 1,773
Schnabel, R. B., Yin, X., Gona, P., Larson, M. G., Beiser, A. S., McManus, D. D., Newton-Cheh, C., Lubitz, S. A., Magnani, J. W., Ellinor, P. T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61774-8 · Cited by 1,746
Self-citationDewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719
Stroke Prevention in Atrial Fibrillation Study. Final results.
Prevention, S., & Atrial Fibrillation Investigators (1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis‐Holland, J. E., Bangalore, S., Bates, E., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,691
Self-citationAppendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
Blackshear, J. L., & Odell, J. A. (1996) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00887-x · Cited by 1,686
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E. A., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J. H., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001029 · Cited by 1,684
Self-citationStout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000603 · Cited by 1,602
Self-citationPrevention of bleeding in patients with atrial fibrillation undergoing PCI
Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611594 · Cited by 1,590
Rhythm control versus rate control for atrial fibrillation and heart failure
Roy, D., Talajic, M., Nattel, S., Wyse, D. G., Dorian, P., Lee, K. L., Bourassa, M. G., Arnold, J. M. O., Buxton, A. E., Camm, A. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708789 · Cited by 1,585
Packer, D. L., Mark, D. B., Robb, R. A., Monahan, K. H., Bahnson, T. D., Poole, J. E., Noseworthy, P. A., Rosenberg, Y., Jeffries, N. O., Mitchell, L. B., et al. (2019) · JAMA · doi:10.1001/jama.2019.0693 · Cited by 1,538
Self-citationEpidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study
Wolf, P. A., Dawber, T. R., Thomas, H. E., & Kannel, W. B. (1978) · Neurology · doi:10.1212/wnl.28.10.973 · Cited by 1,526
Dabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506
Kück, K., Cappato, R., Siebels, J., & Rüppel, R. (2000) · Circulation · doi:10.1161/01.cir.102.7.748 · Cited by 1,474
Marrouche, N. F., Wilber, D., Hindricks, G., Jais, P., Akoum, N., Marchlinski, F., Kholmovski, E., Burgon, N., Hu, N., Mont, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.3 · Cited by 1,473
The surgical treatment of atrial fibrillation
Cox, J. L., Schuessler, R. B., D’Agostino, H. J., Stone, C. M., Chang, B.-C., Cain, M. E., Corr, P. B., & Boineau, J. P. (1991) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)36684-x · Cited by 1,464
Electrical, contractile and structural remodeling during atrial fibrillation
Allessie, M. A. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00258-4 · Cited by 1,455
Obesity and the risk of new-onset atrial fibrillation
Wang, T. J. (2004) · JAMA · doi:10.1001/jama.292.20.2471 · Cited by 1,427
Jackman, W. M., Wang, X., Friday, K. J., Roman, C. A., Moulton, K. P., Beckman, K. J., McClelland, J. H., Twidale, N., Hazlitt, H. A., Prior, M. I., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242301 · Cited by 1,422
C-Reactive Protein Elevation in Patients With Atrial Arrhythmias
Chung, M. K., Martin, D. O., Sprecher, D. L., Wazni, O. M., KANDERIAN, A. S., Carnes, C. A., Bauer, J. A., TCHOU, P. J., Niebauer, M. J., Natale, A., et al. (2001) · Circulation · doi:10.1161/hc4901.101760 · Cited by 1,386
Self-citationDual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708454 · Cited by 1,383
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C. M., Buller, H. R., & Levi, M. M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,353
Klein, I., & Danzi, S. (2007) · Circulation · doi:10.1161/circulationaha.106.678326 · Cited by 1,324
Colilla, S., Crow, A., Petkun, W., Singer, D. E., Simon, T. A., & Liu, X. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.05.063 · Cited by 1,323
US Health Care Spending by Payer and Health Condition, 1996-2016
Dieleman, J. L., Cao, J., Chapin, A., Chen, C., Li, Z., Liu, A., Horst, C., Kaldjian, A., Matyasz, T., Scott, K. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.0734 · Cited by 1,313
Brugada, J., Katritsis, D. G., Arbelo, E., Arribas, F., Bax, J. J., Blomström‐Lundqvist, C., Calkins, H. G., Corrado, D., Deftereos, S. G., Diller, G., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz467 · Cited by 1,312
Self-citationAtrial fibrillation in patients with cryptogenic stroke
Gladstone, D. J., Spring, M., Dorian, P., Panzov, V., Thorpe, K. E., Hall, J., Vaid, H., O'Donnell, M., Laupacis, A., Côté, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311376 · Cited by 1,276
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal
Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00031.2009 · Cited by 1,273
A multicenter risk index for atrial fibrillation after cardiac surgery
Mathew, J. P. (2004) · JAMA · doi:10.1001/jama.291.14.1720 · Cited by 1,234
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
Lopes, R. D., Heizer, G., Aronson, R., Vora, A. N., Massaro, T., Mehran, R., Goodman, S. G., Windecker, S., Darius, H., Li, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817083 · Cited by 1,228
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Douketis, J. D., Spyropoulos, A. C., Kaatz, S., Becker, R. C., Caprini, J. A., Dunn, A. S., Garcia, D. A., Jacobson, A., Jaffer, A. K., Kong, D. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501035 · Cited by 1,184
Wilber, D. J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., Macle, L., Daoud, E. G., Calkins, H., Hall, B., et al. (2010) · JAMA · doi:10.1001/jama.2009.2029 · Cited by 1,170
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Pollack, C. V., Reilly, P. A., van Ryn, J., Eikelboom, J. W., Glund, S., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kam, C. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707278 · Cited by 1,148
Criteria for Evaluation of Novel Markers of Cardiovascular Risk
Hlatky, M. A., Greenland, P., Arnett, D. K., Ballantyne, C. M., Criqui, M. H., Elkind, M. S. V., Go, A. S., Harrell, F. E., Hong, Y., Howard, B. V., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192278 · Cited by 1,146
Self-citationAmiodarone to Prevent Recurrence of Atrial Fibrillation
Roy, D., Talajic, M. R., Dorian, P., Connolly, S. J., Eisenberg, M. J., Green, M. S., Kuś, T., Lambert, J., Dubuc, M., Gagné, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421302 · Cited by 1,142
2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease
Stout, K., Daniels, C. J., Aboulhosn, J., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M. Z., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1029 · Cited by 1,135
Self-citationEffect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C. T., & Connolly, S. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803778 · Cited by 1,125
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124
Wazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121
Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.
Vaziri, S. M., Larson, M. G., Benjamin, E. J., & Levy, D. (1994) · Circulation · doi:10.1161/01.cir.89.2.724 · Cited by 1,073
Self-citationThromboembolic and bleeding complications in patients with mechanical heart valve prostheses.
Cannegieter, S. C., Rosendaal, F. R., & Briët, E. (1994) · Circulation · doi:10.1161/01.cir.89.2.635 · Cited by 1,072
5-Year Outcomes After Left Atrial Appendage Closure
Reddy, V. Y., Doshi, S. K., Kar, S., Gibson, D. N., Price, M. J., Huber, K., Horton, R., Buchbinder, M., Neužil, P., Gordon, N. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.021 · Cited by 1,060
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P. M., Wang, Y., Wang, Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802686 · Cited by 1,041
Schnabel, R. B., SULLIVAN, L. M., Levy, D. A., Pencina, M. J., Massaro, J. M., D’Agostino, R. B., Newton‐Cheh, C., Yamamoto, J. F., Magnani, J. W., Tadros, T. M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60443-8 · Cited by 1,038
Self-citationLong-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort
Pathak, R. K., Middeldorp, M. E., Meredith, M., Mehta, A. B., Mahajan, R., Wong, C. X., Twomey, D., Elliott, A. D., Kalman, J. M., Abhayaratna, W. P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.002 · Cited by 1,036
Self-citationLenient versus strict rate control in patients with atrial fibrillation
Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001337 · Cited by 1,033
Reddy, V. Y., Sievert, H., Halperin, J., Doshi, S. K., Buchbinder, M., Neuzil, P., Huber, K., Whisenant, B., Kar, S., Swarup, V., et al. (2014) · JAMA · doi:10.1001/jama.2014.15192 · Cited by 1,018
Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction
The Cardiac Arrhythmia Suppression Trial II Investigators* (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270403 · Cited by 1,012
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
Torp-Pedersen, C. T., Møller, M., Bloch-Thomsen, P.-E., Køber, L., Sandøe, E., Egstrup, K., Agner, E., Carlsen, J. E., Videbæk, J., Marchant, B., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411201 · Cited by 1,012
Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., & Radford, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.017 · Cited by 1,008
Ommen, S. R., Mital, S. R., Burke, M. A., Day, S. M., Deswal, A. M., Elliot, P. M., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P. F., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.044 · Cited by 997
Self-citationVentricular Pacing or Dual-Chamber Pacing for Sinus-Node Dysfunction
Lamas, G. A., Lee, K. L., Sweeney, M. O., Silverman, R., León, A. R., Yee, R. K., Marinchak, R. A., Flaker, G., SCHRON, E. B., Orav, E. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013040 · Cited by 994
KCNQ1 Gain-of-Function Mutation in Familial Atrial Fibrillation
Chen, Y.-H., Xu, S.-J., Bendahhou, S., Wang, X.-L., Wang, Y., Xu, W.-Y., Jin, H., Sun, H., Su, X.-Y., Zhuang, Q.-N., et al. (2003) · Science · doi:10.1126/science.1077771 · Cited by 989
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Crowther, M. A., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Lawrence, J. H., Yue, P., Bronson, M. D., Lu, G., Conley, P. B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814051 · Cited by 977
Circumferential Pulmonary-Vein Ablation for Chronic Atrial Fibrillation
Oral, H., Pappone, C., Chugh, A., Good, E. D., Bogun, F. M., Pelosi, F., Bates, E., Lehmann, M. H., Vicedomini, G., Augello, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa050955 · Cited by 975
Increased Mortality after Dronedarone Therapy for Severe Heart Failure
Køber, L., Torp-Pedersen, C. T., McMurray, J. J. V., Gøtzsche, O., Lévy, S., Crijns, H. J. G. M., Amlie, J., & Carlsen, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800456 · Cited by 969
Linde, C. M., Leclercq, C., Rex, S., Garrigue, S., Lavergne, T., Cazeau, S., McKenna, W. J., Fitzgerald, M., Deharo, J., Alonso, C., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01932-0 · Cited by 965
Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
Klein, A. L., Grimm, R. A., Murray, R. D., Apperson-Hansen, C., ASINGER, R. W., Black, I. W., Davidoff, R., Erbel, R., Halperin, J. L., Orsinelli, D. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441901 · Cited by 952
Pathak, R. K., Middeldorp, M. E., Lau, D. H., Mehta, A. B., Mahajan, R., Twomey, D., Alasady, M., Hanley, L., Antic, N. A., McEvoy, R. D., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.028 · Cited by 949
Self-citationCryoballoon Ablation of Pulmonary Veins for Paroxysmal Atrial Fibrillation
Packer, D. L., Kowal, R. C., Wheelan, K. R., Irwin, J. M., Champagne, J., Guerra, P. G., Dubuc, M., Reddy, V. Y., Nelson, L., Holcomb, R. G., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.064 · Cited by 919
Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure
Hsu, L., Jaı̈s, P., Sanders, P., Garrigue, S., Hocini, M., Sacher, F., Takahashi, Y., Rotter, M., Pasquié, J., Scavée, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041018 · Cited by 890
Self-citationCatheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation
Jaı̈s, P., CAUCHEMEZ, B., Macle, L., Daoud, E. G., Khairy, P., Subbiah, R. N., Hocini, M., Extramiana, F., Sacher, F., Bordachar, P., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.772582 · Cited by 889
Odutayo, A., Wong, C. X. J., Hsiao, A. J., Hopewell, S., Altman, D. G., & Emdin, C. A. (2016) · BMJ · doi:10.1136/bmj.i4482 · Cited by 888
Alonso, Á., Krijthe, B. P., Aspelund, T., Stepas, K. A., Pencina, M. J., Moser, C., Sinner, M. F., Sotoodehnia, N., Fontes, J. D., Janssens, A. C. J. W., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000102 · Cited by 886
Self-citationBiase, L. D., Mohanty, P. K., Mohanty, S., Santangeli, P., Trivedi, C. G., Lakkireddy, D., Reddy, M., Jaı̈s, P., Themistoclakis, S., Russo, A. D., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019406 · Cited by 880
Self-citationAtrial Fibrillation Pathophysiology
Iwasaki, Y., Nishida, K., Kato, T., & Nattel, S. (2011) · Circulation · doi:10.1161/circulationaha.111.019893 · Cited by 879
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology
Nielsen, J. B., Thorolfsdottir, R. B., Fritsche, L. G., Zhou, W., Skov, M. W., Graham, S. E., Herron, T. J., McCarthy, S., Schmidt, E. M., Sveinbjornsson, G., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0171-3 · Cited by 876
Atrial Fibrillation Begets Heart Failure and Vice Versa
Santhanakrishnan, R., Wang, N., Larson, M. G., Magnani, J. W., McManus, D. D., Lubitz, S. A., Ellinor, P. T., Cheng, S. C., Vasan, R. S., Lee, D. S., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.018614 · Cited by 874
Self-citationA New Risk Scheme to Predict Warfarin-Associated Hemorrhage
Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N. V., & Singer, D. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.031 · Cited by 864
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E. A., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J. H., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.053 · Cited by 849
Self-citationCalkins, H., Reynolds, M. R., Spector, P., Sondhi, M., Xu, Y., Martin, A., Williams, C. J., & Sledge, I. (2009) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.108.824789 · Cited by 847
Andersen, H. R., Nielsen, J. C., Thomsen, P. E. B., Thuesen, L., Mortensen, P. T., Vesterlund, T., & Pedersen, A. K. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03425-9 · Cited by 841
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
Andrade, J. G., Wells, G. A., Deyell, M. W., Bennett, M. T., Essebag, V., Champagne, J., Roux, J.-F., Yung, D., Skanes, A. C., Khaykin, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2029980 · Cited by 841
Self-citationVentricular fibrillation in the Wolff-Parkinson-White syndrome
Klein, G. J., Bashore, T. M., Sellers, T. D., Pritchett, E. L. C., Smith, W. M., & Gallagher, J. J. (1979) · New England Journal of Medicine · doi:10.1056/nejm197911153012003 · Cited by 830
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 828
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
Diener, H., Sacco, R. L., Easton, J. D., Granger, C. B., Bernstein, R. A., Uchiyama, S., Kreuzer, J., Cronin, L., Cotton, D., Grauer, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813959 · Cited by 826
Healey, J. S., Baranchuk, A., Crystal, E., Morillo, C. A., Garfinkle, M., Yusuf, S., & Connolly, S. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.070 · Cited by 822
Role of the Autonomic Nervous System in Atrial Fibrillation
Chen, P., Chen, L. S., Fishbein, M. C., Lin, S., & Nattel, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.303772 · Cited by 820
Self-citationSarode, R., Milling, T. J., Refaai, M. A., Mangione, A., Schneider, A., Durn, B. L., & Goldstein, J. N. (2013) · Circulation · doi:10.1161/circulationaha.113.002283 · Cited by 812
Ganesan, A. N., Shipp, N. J., Brooks, A. G., Kuklik, P., Lau, D. H., Lim, H. S., Sullivan, T., Roberts‐Thomson, K. C., & Sanders, P. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.004549 · Cited by 800
Self-citationGoette, A., Kalman, J. M., Aguinaga, L., Akar, J. G., Cabrera, J. Á., Chen, S. A., Chugh, S. S., Corradi, D., d’Ávila, A., Dobrev, D., et al. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2016.05.028 · Cited by 791
Self-citationAbed, H. S., Wittert, G. A., Leong, D. P., Shirazi, M. G., Bahrami, B., Middeldorp, M. E., Lorimer, M. F., Lau, D. H., Antic, N. A., Brooks, A. G., et al. (2013) · JAMA · doi:10.1001/jama.2013.280521 · Cited by 776
Self-citationAssociation of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R., & Krumholz, H. M. (2003) · JAMA · doi:10.1001/jama.289.7.871 · Cited by 772
Multi-ethnic genome-wide association study for atrial fibrillation
Roselli, C., Chaffin, M. D., Weng, L.-C. C., Aeschbacher, S., Ahlberg, G., Albert, C. M., Almgren, P., Alonso, Á., Anderson, C. D., Aragam, K. G., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0133-9 · Cited by 761
Self-citationGlotzer, T. V., Hellkamp, A. S., Zimmerman, J., Sweeney, M. O., Yee, R., Marinchak, R., Cook, J., Paraschos, A., Love, J., Radoslovich, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000057981.70380.45 · Cited by 750
Amiodarone versus sotalol for atrial fibrillation
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041705 · Cited by 749
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
Whitlock, R. P., Belley‐Côté, E. P., Paparella, D., Healey, J. S., Brady, K., Sharma, M., Reents, W., Budera, P., Baddour, A. J., Fila, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101897 · Cited by 741
Thyroid hormones and cardiovascular disease
Jabbar, A., Pingitore, A., Pearce, S. H. S., Zaman, A., Iervasi, G., & Razvi, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.174 · Cited by 729
Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., Sick, P., & Sievert, H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.035 · Cited by 727
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation
Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., Pehrson, S., Englund, A., Hartikainen, J., Mortensen, L. S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113566 · Cited by 720
Stangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 720
Vranckx, P., Valgimigli, M., Eckardt, L., Tijssen, J. G. P., Lewalter, T., Gargiulo, G., Batushkin, V., Campo, G. C., Lysak, Z., Ip, V., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31872-0 · Cited by 712
Khairy, P., Van Hare, G. F., Balaji, S., Berul, C. I., Cecchin, F., Cohen, M. I., Daniels, C. J., Deal, B. J., Dearani, J. A., Groot, N. D., et al. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.05.009 · Cited by 709
Huxley, R. R., Lopez, F. L., Folsom, A. R., Agarwal, S. K., Loehr, L. R., Soliman, E. Z., Maclehose, R., Konety, S., & Alonso, A. (2011) · Circulation · doi:10.1161/circulationaha.110.009035 · Cited by 697
Sposato, L. A., Cipriano, L. E., Saposnik, G., Vargas, E. R., Riccio, P. M., & Hachinski, V. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70027-x · Cited by 694
Pappone, C., Augello, G., Sala, S., Gugliotta, F., Vicedomini, G., Gulletta, S., Paglino, G., Mazzone, P., Sora, N., Greiss, I., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.037 · Cited by 685
Temporal relationship between subclinical atrial fibrillation and embolic events
Brambatti, M., Connolly, S. J., Gold, M. R., Morillo, C. A., Capucci, A., Muto, C., Lau, C. P., Van Gelder, I. C., Hohnloser, S. H., Carlson, M., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007825 · Cited by 676
Osmancik, P. P., Heřman, D., Neužil, P., Hála, P., Táborský, M., Kala, P., Poloczek, M., Šťásek, J., Haman, L., Branny, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.067 · Cited by 674
Morillo, C. A., Verma, A., Connolly, S. J., Kuck, K. H., Nair, G. M., Champagne, J., Sterns, L. D., Beresh, H., Healey, J. S., Natale, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.467 · Cited by 667
Electrical reversion of cardiac arrhythmias.
Lown, B. (1967) · Heart · doi:10.1136/hrt.29.4.469 · Cited by 664
Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation
Yao, C., Veleva, T., Scott, L., Cao, S., Li, L., Chen, G., Jeyabal, P., Pan, X., Alsina, K. M., Abu-Taha, I., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035202 · Cited by 661
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction
Prabhu, S., Taylor, A. J., Costello, B. T., Kaye, D. M., McLellan, A. J. A., Voskoboinik, A., Sugumar, H., Lockwood, S. M., Stokes, M. B., Pathik, B., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.041 · Cited by 661
Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation
Wazni, O. M., Dandamudi, G., Sood, N. A., HOYT, R. H., Tyler, J. D., Durrani, S., Niebauer, M. J., Makati, K. J., Halperin, B. D., Gauri, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2029554 · Cited by 656
Tsang, T. S. M., Gersh, B. J., Appleton, C. P., Tajik, A. J., Barnes, M. E., Bailey, K. R., Oh, J. K., Leibson, C. L., Montgomery, S. C., & Seward, J. B. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02373-2 · Cited by 652
Mark, D. B., Anstrom, K. J., Sheng, S., Piccini, J. P., Baloch, K. N., Monahan, K. H., Daniels, M. R., Bahnson, T. D., Poole, J. E., Rosenberg, Y., et al. (2019) · JAMA · doi:10.1001/jama.2019.0692 · Cited by 650
Self-citationBiase, L. D., Burkhardt, J. D., Mohanty, P. K., Sánchez, J., Mohanty, S., Horton, R., Gallinghouse, G. J., BAILEY, S. M., ZAGRODZKY, J. D., Santangeli, P., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.928903 · Cited by 648
Self-citation2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.045 · Cited by 643
Self-citationDronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter
Singh, B. N., Connolly, S. J., Crijns, H. J. G. M., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E., & Hohnloser, S. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054686 · Cited by 638
Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage
Flibotte, J. J., Hagan, N., O’Donnell, J. S., Greenberg, S. M., & Rosand, J. M. (2004) · Neurology · doi:10.1212/01.wnl.0000138428.40673.83 · Cited by 632
Voigt, N., Li, N., Wang, Q., Wang, W., Trafford, A. W., Abu-Taha, I., Sun, Q., Wieland, T., Ravens, U., Nattel, S., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.067306 · Cited by 630
Dronedarone in High-Risk Permanent Atrial Fibrillation
Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., Atar, D., Avezum, Á., Blomström, P., Borggrefe, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109867 · Cited by 628
Patti, G., Chello, M., Candura, D., Pasceri, V., D’Ambrosio, A., Covino, E., & Sciascio, G. D. (2006) · Circulation · doi:10.1161/circulationaha.106.621763 · Cited by 617
Atrial L-type Ca2+ currents and human atrial fibrillation.
Wagoner, D. V. V., Pond, A. L., Lamorgese, M., Rossie, S., McCarthy, P., & Nerbonne, J. (1999) · Circulation Research · doi:10.1161/01.res.85.5.428 · Cited by 617
Self-citationDuration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
Gelder, I. C. V., Healey, J. S., Crijns, H. J. G. M., Wang, J., Hohnloser, S. H., Gold, M. R., Capucci, A., Lau, C., Morillo, C. A., Hobbelt, A. H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx042 · Cited by 604
Udo, E. O., Zuithoff, N. P. A., van Hemel, N. M., de Cock, C. C., Hendriks, T., Doevendans, P. A., & Moons, K. G. M. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2011.12.014 · Cited by 597
Left Ventricular‐Based Cardiac Stimulation Post AV Nodal Ablation Evaluation (The PAVE Study)
Doshi, R. N., Daoud, E. G., Fellows, C. L., TURK, K. T., Duran, A., Hamdan, M. H., Pires, L. A., & for the PAVE Study Group (2005) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2005.50062.x · Cited by 596
Calcium Signaling and Cardiac Arrhythmias
Landstrom, A. P., Dobrev, D., & Wehrens, X. H. T. (2017) · Circulation Research · doi:10.1161/circresaha.117.310083 · Cited by 596
Page, R. L., Joglar, J. A., Caldwell, M. A., Calkins, H., Conti, J. B., Deal, B. J., Estes, N. A. M., Field, M. E., Goldberger, Z. D., Hammill, S. C., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000311 · Cited by 595
Self-citationAndrade, J. G., Aguilar, M., Atzema, C. L., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 593
Self-citationPacemaker or Defibrillator Surgery without Interruption of Anticoagulation
Birnie, D. H., Healey, J. S., Wells, G. A., Verma, A., TANG, A. S. L., Krahn, A. D., Simpson, C. S., Paredes, F. A., Coutu, B., Leiria, T. L. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302946 · Cited by 589
Self-citationDetermination of Therapeutic and Toxic Serum Digoxin Concentrations by Radioimmunoassay
Smith, T. W., Butler, V. P., & Haber, E. (1969) · New England Journal of Medicine · doi:10.1056/nejm196911272812203 · Cited by 585
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Yasuda, S., Kaikita, K., Akao, M., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904143 · Cited by 585
Deshmukh, A. J., Patel, N., Pant, S., Shah, N. N., Chothani, A., Mehta, K. D., Grover, P. M., Singh, V., Vallurupalli, S., Savani, G. T., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003862 · Cited by 580
Self-citationOlsson, L. G., Swedberg, K., Ducharme, A., Granger, C. B., Michelson, E. L., McMurray, J. J. V., Puu, M., Yusuf, S., & Pfeffer, M. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.060 · Cited by 574
Kuramatsu, J. B., Gerner, S. T., Schellinger, P. D., Glahn, J., Endres, M., Sobesky, J., Flechsenhar, J., Neugebauer, H., Jüttler, E., Grau, A., et al. (2015) · JAMA · doi:10.1001/jama.2015.0846 · Cited by 568
Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch
Tison, G. H., Sanchez, J. M., Ballinger, B., Singh, A., Olgin, J. E., Pletcher, M. J., Vittinghoff, E., Lee, E. S., Fan, S. M., Gladstone, R. A., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0136 · Cited by 566
Self-citationPiccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N., Hernandez, A. F., Heckbert, S. R., Benjamin, E. J., & Curtis, L. H. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.962688 · Cited by 565
Self-citationChung, M. K., Eckhardt, L. L., Chen, L. Y., Ahmed, H. M., Gopinathannair, R., Joglar, J. A., Noseworthy, P. A., Pack, Q. R., Sanders, P., & Trulock, K. M. (2020) · Circulation · doi:10.1161/cir.0000000000000748 · Cited by 565
Self-citationLópez-López, J. A., Sterne, J. A. C., Thom, H. H. Z., Higgins, J. P. T., Hingorani, A. D., Okoli, G. N., Davies, P. A., Bodalia, P. N., Bryden, P. A., Welton, N. J., et al. (2017) · BMJ · doi:10.1136/bmj.j5058 · Cited by 563
Outward K + Current Densities and Kv1.5 Expression Are Reduced in Chronic Human Atrial Fibrillation
Wagoner, D. R. V., Pond, A. L., McCarthy, P. M., Trimmer, J. S., & Nerbonne, J. M. (1997) · Circulation Research · doi:10.1161/01.res.80.6.772 · Cited by 556
Self-citationIdentification of a Genetic Locus for Familial Atrial Fibrillation
Brugada, R., Tapscott, T., Czernuszewicz, G. Z., Marian, A. J., Iglesias, A., Mont, L., Brugada, J., Girona, J. M., Domingo, A., Bachinski, L. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703273361302 · Cited by 554
Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation
Alonso, Á., Norby, F. L., Matsushita, K., Loehr, L. R., Agarwal, S. K., Chen, L. Y., Soliman, E. Z., Astor, B. C., & Coresh, J. (2011) · Circulation · doi:10.1161/circulationaha.111.020982 · Cited by 549
Self-citationViles-González, J. F., Kar, S., Douglas, P. S., Dukkipati, S. R., Feldman, T. E., Horton, R., Holmes, D. R., & Reddy, V. Y. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.028 · Cited by 545
Pathak, R. K., Elliott, A., Middeldorp, M. E., Meredith, M., Mehta, A. B., Mahajan, R., Hendriks, J. M. L., Twomey, D., Kalman, J. M., Abhayaratna, W. P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.488 · Cited by 544
Self-citationPerioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
Douketis, J. D., Spyropoulos, A. C., Duncan, J. M., Carrier, M., Gal, G. L., Tafur, A. J., Vanassche, T., Verhamme, P. B., Shivakumar, S., Gross, P. L., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2431 · Cited by 538
Manning, W. J., Silverman, D. I., Katz, S. E., Riley, M. F., Come, P. C., Doherty, R. M., Munson, J. T., & Douglas, P. S. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90652-1 · Cited by 532
Stoddard, M. F., Dawkins, P. R., Prince, C. R., & Ammash, N. M. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00396-8 · Cited by 531
Melenovský, V., Hwang, S., Redfield, M. M., Zakeri, R., Lin, G., & Borlaug, B. A. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001667 · Cited by 527
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery
Arsenault, K. A., Yusuf, A. M., Crystal, E., Healey, J. S., Morillo, C. A., Nair, G. M., & Whitlock, R. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003611.pub3 · Cited by 523
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
Anderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000042 · Cited by 521
Self-citationGoldstein, R. E., Boccuzzi, S. J., Cruess, D., & Nattel, S. (1991) · Circulation · doi:10.1161/01.cir.83.1.52 · Cited by 521
Minimizing Ventricular Pacing to Reduce Atrial Fibrillation in Sinus-Node Disease
Sweeney, M. O., Bank, A. J., Nsah, E., Koullick, M., Zeng, Q. C., Hettrick, D. A., Sheldon, T., & Lamas, G. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071880 · Cited by 518
Thyroid Hormones and Cardiovascular Function and Diseases
Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., Peeters, R., Zaman, A., & Iervasi, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.045 · Cited by 515
Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., & Xu, Y. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.796185 · Cited by 514
DEEDWANIA, P. C., Singh, B. N., Ellenbogen, K. A., Fisher, S. G., Fletcher, R. D., & Singh, S. N. (1998) · Circulation · doi:10.1161/01.cir.98.23.2574 · Cited by 505
Hunter, R. J., Berriman, T., Diab, I. G., Kamdar, R., Richmond, L., Baker, V., Goromonzi, F., Sawhney, V., Duncan, E. R., Page, S. P., et al. (2014) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.113.000806 · Cited by 504
Stabile, G., Bertaglia, E., Senatore, G., Simone, A. D., Zoppo, F., Donnici, G., Turco, P., Pascotto, P., FAZZARI, M., & Vitale, D. F. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi583 · Cited by 502
The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation
Tedrow, U. B., Conen, D., Ridker, P. M., Cook, N. R., Koplan, B. A., Manson, J. E., Buring, J. E., & Albert, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.029 · Cited by 500
Munger, T. M., Packer, D. L., Hammill, S. C., Feldman, B. J., Bailey, K. R., Ballard, D. J., Holmes, D. R., & Gersh, B. J. (1993) · Circulation · doi:10.1161/01.cir.87.3.866 · Cited by 500
Siontis, K. C., Zhang, X., Eckard, A., Bhave, N. M., Schaubel, D. E., He, K., Tilea, A. M., Stack, A. G., Balkrishnan, R., Yao, X., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035418 · Cited by 499
Self-citationHealey, J. S., Crystal, E., Lamy, A., Teoh, K., Semelhago, L., Hohnloser, S. H., Cybulsky, I., Abouzahr, L., Sawchuck, C., Carroll, S., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.054 · Cited by 496
Pedersen, O. D., Bagger, H., Keller, N., Marchant, B., Køber, L., & Torp-Pedersen, C. (2001) · Circulation · doi:10.1161/01.cir.104.3.292 · Cited by 496
Walkey, A. J., Wiener, R. S., Ghobrial, J. M., Curtis, L. H., & Benjamin, E. J. (2011) · JAMA · doi:10.1001/jama.2011.1615 · Cited by 493
Self-citationAblation Versus Drug Therapy for Atrial Fibrillation in Heart Failure
Packer, D. L., Piccini, J. P., Monahan, K. H., Al‐Khalidi, H. R., Silverstein, A. P., Noseworthy, P. A., Poole, J. E., Bahnson, T. D., Lee, K. L., Mark, D. B., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050991 · Cited by 493
Self-citationRoden, D. M., Woosley, R. L., & Primm, R. K. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90010-4 · Cited by 489
Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation
Guo, Y., Wang, H., Zhang, H., Liu, T., Liang, Z., Xia, Y., Yan, L., Xing, Y., Shi, H., Li, S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.019 · Cited by 489
Stambler, B. S., Wood, M. A., Ellenbogen, K. A., Perry, K. T., Wakefield, L. K., & VanderLugt, J. T. (1996) · Circulation · doi:10.1161/01.cir.94.7.1613 · Cited by 485
Jones, D. G., Haldar, S. K., Hussain, W., Sharma, R., Francis, D. P., Rahman-Haley, S. L., McDonagh, T. A., Underwood, S. R., Markides, V., & Wong, T. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.069 · Cited by 481
Flagged first, then by citations
20 of the 1396 references couldn’t be matched to a known paper.
Research works printed but not linked: 246
- Schnabel, 2015, 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, Lancet, 386, 154, 10.1016/S0140-6736(14)61774-8 · DOI · Paper page
- Mou, 2018, Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities), Circ Arrhythm Electrophysiol, 11, 10.1161/CIRCEP.118.006350 · DOI
- Haissaguerre, 1998, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, 659, 10.1056/NEJM199809033391003 · DOI
- Haissaguerre, 1998, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, 659, 10.1056/NEJM199809033391003 · DOI
- Voigt, 2010, Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation, Circ Arrhythm Electrophysiol, 3, 472, 10.1161/CIRCEP.110.954636 · DOI
- Lubitz, 2010, Association between familial atrial fibrillation and risk of new-onset atrial fibrillation, JAMA, 304, 2263, 10.1001/jama.2010.1690 · DOI · Paper page
- Roselli, 2018, Multi-ethnic genome-wide association study for atrial fibrillation, Nat Genet, 50, 1225, 10.1038/s41588-018-0133-9 · DOI
- Lunde, 2018, Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review, Expert Rev Cardiovasc Ther, 16, 857, 10.1080/14779072.2018.1533118 · DOI
- Kunneman, 2020, Assessment of shared decision-making for stroke prevention in patients with atrial fibrillation: a randomized clinical trial, JAMA Intern Med, 180, 1215, 10.1001/jamainternmed.2020.2908 · DOI
- Alonso, 2013, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium, J Am Heart Assoc, 2
- Shang, 2016, Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies, PLoS One, 11, 10.1371/journal.pone.0155581 · DOI
- Perez, 2019, Large-scale assessment of a smartwatch to identify atrial fibrillation, N Engl J Med, 381, 1909, 10.1056/NEJMoa1901183 · DOI · Paper page
- Aune, 2018, Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta-analysis of prospective studies, Eur J Prev Cardiol, 25, 1437, 10.1177/2047487318780435 · DOI
- Aune, 2018, Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies, J Diabetes Complications, 32, 501, 10.1016/j.jdiacomp.2018.02.004 · DOI
- Soliman, 2020, Effect of intensive blood pressure lowering on the risk of atrial fibrillation, Hypertension, 75, 1491, 10.1161/HYPERTENSIONAHA.120.14766 · DOI
- Alonso, 2013, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium, J Am Heart Assoc, 2
- Himmelreich, 2020, Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis, Europace, 22, 684, 10.1093/europace/euaa005 · DOI
- Roselli, 2018, Multi-ethnic genome-wide association study for atrial fibrillation, Nat Genet, 50, 1225, 10.1038/s41588-018-0133-9 · DOI
- Huxley, 2011, Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 123, 1501, 10.1161/CIRCULATIONAHA.110.009035 · DOI · Paper page
- Mishima, 2021, Self-reported physical activity and atrial fibrillation risk: a systematic review and meta-analysis, Heart Rhythm, 18, 520, 10.1016/j.hrthm.2020.12.017 · DOI
- Newman, 2021, Risk of atrial fibrillation in athletes: a systematic review and meta-analysis, Br J Sports Med, 55, 1233, 10.1136/bjsports-2021-103994 · DOI · Paper page
- Marcus, 2021, Acute consumption of alcohol and discrete atrial fibrillation events, Ann Intern Med, 174, 1503, 10.7326/M21-0228 · DOI
- Lu, 2021, Genetically determined tobacco and alcohol use and risk of atrial fibrillation, BMC Med Genomics, 14, 73, 10.1186/s12920-021-00915-0 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Middeldorp, 2018, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study, Europace, 20, 1929, 10.1093/europace/euy117 · DOI
- Di Benedetto, 2018, Individual and combined impact of lifestyle factors on atrial fibrillation in apparently healthy men and women: the EPIC-Norfolk prospective population study, Eur J Prev Cardiol, 25, 1374, 10.1177/2047487318782379 · DOI
- Donnellan, 2019, Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort, Circ Arrhythm Electrophysiol, 12, 10.1161/CIRCEP.119.007598 · DOI
- Donnellan, 2019, Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation, Europace, 21, 1476, 10.1093/europace/euz183 · DOI
- Donnellan, 2020, Impact of bariatric surgery on atrial fibrillation type, Circ Arrhythm Electrophysiol, 13, 10.1161/CIRCEP.119.007626 · DOI
- Mohanty, 2018, Impact of weight loss on ablation outcome in obese patients with longstanding persistent atrial fibrillation, J Cardiovasc Electrophysiol, 29, 246, 10.1111/jce.13394 · DOI
- Hegbom, 2007, Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation, Int J Cardiol, 116, 86, 10.1016/j.ijcard.2006.03.034 · DOI
- Malmo, 2016, Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial, Circulation, 133, 466, 10.1161/CIRCULATIONAHA.115.018220 · DOI · Paper page
- Elliott, 2023, An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomized controlled trial, J Am Coll Cardiol EP, 9, 455
- Pathak, 2015, Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study, J Am Coll Cardiol, 66, 985, 10.1016/j.jacc.2015.06.488 · DOI · Paper page
- Oesterle, 2022, Effects of supervised exercise training on atrial fibrillation: a meta-analysis of randomized controlled trials, J Cardiopulm Rehabil Prev, 42, 258, 10.1097/HCR.0000000000000665 · DOI
- Osbak, 2011, A randomized study of the effects of exercise training on patients with atrial fibrillation, Am Heart J, 162, 1080, 10.1016/j.ahj.2011.09.013 · DOI
- Andersen, 2013, Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study, Eur Heart J, 34, 3624, 10.1093/eurheartj/eht188 · DOI · Paper page
- Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 74, e177, 10.1016/j.jacc.2019.03.010 · DOI · Paper page
- Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591 · DOI
- Marcus, 2022, Individualized studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial, JAMA Cardiol, 7, 167, 10.1001/jamacardio.2021.5010 · DOI
- Marcus, 2021, Acute consumption of alcohol and discrete atrial fibrillation events, Ann Intern Med, 174, 1503, 10.7326/M21-0228 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Pathak, 2014, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study, J Am Coll Cardiol, 64, 2222, 10.1016/j.jacc.2014.09.028 · DOI · Paper page
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Middeldorp, 2018, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study, Europace, 20, 1929, 10.1093/europace/euy117 · DOI
- Marcus, 2022, Individualized Studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial, JAMA Cardiol, 7, 167, 10.1001/jamacardio.2021.5010 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Donnellan, 2019, Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation, J Am Coll Cardiol EP, 5, 897
- Neefs, 2017, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 231, 155, 10.1016/j.ijcard.2016.12.029 · DOI · Paper page
- Steinberg, 2020, Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial, JAMA, 323, 248, 10.1001/jama.2019.21187 · DOI · Paper page
- Pathak, 2014, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study, J Am Coll Cardiol, 64, 2222, 10.1016/j.jacc.2014.09.028 · DOI · Paper page
- Pinho-Gomes, 2021, Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis, PLoS Med, 18, 10.1371/journal.pmed.1003599 · DOI
- Parkash, 2017, Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]), Circulation, 135, 1788, 10.1161/CIRCULATIONAHA.116.026230 · DOI · Paper page
- Soliman, 2020, Effect of intensive blood pressure lowering on the risk of atrial fibrillation, Hypertension, 75, 1491, 10.1161/HYPERTENSIONAHA.120.14766 · DOI
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Li, 2021, Effects of continuous positive airway pressure treatment in obstructive sleep apnea patients with atrial fibrillation: a meta-analysis, Medicine (Baltimore), 100
- Yang, 2020, CPAP is associated with decreased risk of AF recurrence in patients with OSA, especially those younger and slimmer: a meta-analysis, J Interv Card Electrophysiol, 58, 369, 10.1007/s10840-020-00738-6 · DOI
- Congrete, 2018, Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis, J Evid Based Med, 11, 145, 10.1111/jebm.12313 · DOI
- Deng, 2018, Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis, Sleep Med, 46, 5, 10.1016/j.sleep.2018.02.013 · DOI
- Qureshi, 2015, Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea, Am J Cardiol, 116, 1767, 10.1016/j.amjcard.2015.08.046 · DOI
- Szymanski, 2015, Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations - a long-term prospective, cross-sectional cohort study, Sleep Breath, 19, 849, 10.1007/s11325-014-1102-x · DOI · Paper page
- Caples, 2019, The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial, Int J Cardiol, 278, 133, 10.1016/j.ijcard.2018.11.100 · DOI · Paper page
- Traaen, 2021, Effect of continuous positive airway pressure on arrhythmia in atrial fibrillation and sleep apnea: a randomized controlled trial, Am J Respir Crit Care Med, 204, 573, 10.1164/rccm.202011-4133OC · DOI
- Hunt, 2022, Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial, Heart Rhythm, 19, 1433, 10.1016/j.hrthm.2022.06.016 · DOI
- Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Rienstra, 2018, Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial, Eur Heart J, 39, 2987, 10.1093/eurheartj/ehx739 · DOI · Paper page
- Hlatky, 2009, Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association, Circulation, 119, 2408, 10.1161/CIRCULATIONAHA.109.192278 · DOI
- Rao, 2015, Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, J Am Heart Assoc, 4
- Steinberg, 2015, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial, Eur Heart J, 36, 288, 10.1093/eurheartj/ehu359 · DOI
- Chao, 2018, Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors, Thromb Haemost, 118, 768, 10.1055/s-0038-1636534 · DOI
- Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 · DOI · Paper page
- Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 · DOI · Paper page
- Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
- Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 · DOI · Paper page
- Singer, 2013, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score, J Am Heart Assoc, 2
- Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 · DOI · Paper page
- Buck, 2021, Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the per diem randomized clinical trial, JAMA, 325, 2160, 10.1001/jama.2021.6128 · DOI
- Eckman, 2011, Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation, Circ Cardiovasc Qual Outcomes, 4, 14, 10.1161/CIRCOUTCOMES.110.958108 · DOI
- Gutiérrez, 2020, Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients, Eur J Cardiothorac Surg, 57, 252
- Holmes, 2014, Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, 64, 1, 10.1016/j.jacc.2014.04.029 · DOI
- Reddy, 2017, 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials, J Am Coll Cardiol, 70, 2964, 10.1016/j.jacc.2017.10.021 · DOI
- Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
- Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 · DOI · Paper page
- Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 · DOI · Paper page
- Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
- Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 · DOI · Paper page
- López-López, 2017, Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis, BMJ, 359, j5058, 10.1136/bmj.j5058 · DOI
- Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 · DOI · Paper page
- Brokmeier, 2021, Off-label use for direct oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension-a systematic review, Ann Pharmacother, 55, 995, 10.1177/1060028020970618 · DOI
- Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 · DOI · Paper page
- Sanna, 2014, Cryptogenic stroke and underlying atrial fibrillation, N Engl J Med, 370, 2478, 10.1056/NEJMoa1313600 · DOI · Paper page
- Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
- Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
- Connolly, 2011, Dronedarone in high-risk permanent atrial fibrillation, N Engl J Med, 365, 2268, 10.1056/NEJMoa1109867 · DOI
- Ulimoen, 2013, Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation, Am J Cardiol, 111, 225, 10.1016/j.amjcard.2012.09.020 · DOI · Paper page
- Nikolaidou, 2009, Chronic atrial fibrillation: a systematic review of medical heart rate control management, Postgrad Med J, 85, 303, 10.1136/pgmj.2008.068908 · DOI · Paper page
- Hohnloser, 2009, Effect of dronedarone on cardiovascular events in atrial fibrillation, Revista Portuguesa de Cardiologia, 28, 345
- Brignole, 1998, Atrioventricular junction ablation and pacemaker therapy versus drug treatment in atrial fibrillation, Cardiol Rev, 15, 49
- D, 2009, Survival of dual chamber pacing post atrioventricular nodal ablation in patients with atrial fibrillation, Heart Rhythm, 6, S406
- Santhanakrishnan, 2016, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction, Circulation, 133, 484, 10.1161/CIRCULATIONAHA.115.018614 · DOI
- Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
- Andrade, 2021, Cryoablation or drug therapy for initial treatment of atrial fibrillation, N Engl J Med, 384, 305, 10.1056/NEJMoa2029980 · DOI
- Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
- Kim, 2021, Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study, BMJ, 373, n991, 10.1136/bmj.n991 · DOI
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Hsu, 2004, Catheter ablation for atrial fibrillation in congestive heart failure, N Engl J Med, 351, 2373, 10.1056/NEJMoa041018 · DOI
- Aryana, 2015, Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization, Heart Rhythm, 12, 1431, 10.1016/j.hrthm.2015.03.028 · DOI · Paper page
- Boersma, 2017, Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial, Heart Rhythm, 14, 1302, 10.1016/j.hrthm.2017.05.038 · DOI
- Lip, 2014, Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study), Am J Cardiol, 113, 480, 10.1016/j.amjcard.2013.10.036 · DOI
- Airaksinen, 2013, Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study, J Am Coll Cardiol, 62, 1187, 10.1016/j.jacc.2013.04.089 · DOI · Paper page
- Dankner, 2009, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management, Cardiology, 112, 270, 10.1159/000151703 · DOI
- Lown, 1967, Electrical reversion of cardiac arrhythmias, Br Heart J, 29, 469, 10.1136/hrt.29.4.469 · DOI
- Crijns, 2014, Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study, Int J Cardiol, 172, 588, 10.1016/j.ijcard.2014.01.099 · DOI
- Stiell, 2011, Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments, Ann Emerg Med, 57, 13, 10.1016/j.annemergmed.2010.07.005 · DOI
- Hindricks, 2021, Eur Heart J, 42, 373, 10.1093/eurheartj/ehaa612 · DOI
- Hernandez-Madrid, 2013, Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey, Europace, 15, 915, 10.1093/europace/eut143 · DOI
- Pisters, 2012, Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey, Europace, 14, 666, 10.1093/europace/eur406 · DOI
- Brandes, 2020, Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure, Europace, 22, 1149, 10.1093/europace/euaa057 · DOI
- Dankner, 2009, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management, Cardiology, 112, 270, 10.1159/000151703 · DOI
- Oral, 1999, Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment, N Engl J Med, 340, 1849, 10.1056/NEJM199906173402401 · DOI
- Pedersen, 2001, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy, Circulation, 104, 292, 10.1161/01.CIR.104.3.292 · DOI · Paper page
- Deedwania, 1998, Circulation, 98, 2574, 10.1161/01.CIR.98.23.2574 · DOI
- Brembilla-Perrot, 2001, Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias, Int J Cardiol, 80, 7, 10.1016/S0167-5273(01)00459-4 · DOI
- Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
- Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
- Kober, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456 · DOI
- Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
- Abraham, 2015, Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter, Circ Arrhythm Electrophysiol, 8, 772, 10.1161/CIRCEP.114.002339 · DOI
- Pedersen, 2001, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy, Circulation, 104, 292, 10.1161/01.CIR.104.3.292 · DOI · Paper page
- Alboni, 2004, Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach, N Engl J Med, 351, 2384, 10.1056/NEJMoa041233 · DOI · Paper page
- Andrade, 2018, Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation, Heart Rhythm, 15, 9, 10.1016/j.hrthm.2017.10.002 · DOI
- Azpitarte, 1997, Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study, Eur Heart J, 18, 1649, 10.1093/oxfordjournals.eurheartj.a015146 · DOI
- Markman, 2022, Safety of pill-in-the-pocket class 1C antiarrhythmic drugs for atrial fibrillation, J Am Coll Cardiol EP, 8, 1515
- Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
- Hamilton, 2020, Amiodarone: a comprehensive guide for clinicians, Am J Cardiovasc Drugs, 20, 549, 10.1007/s40256-020-00401-5 · DOI
- Tisdale, 2020, Drug-induced arrhythmias: a scientific statement from the American Heart Association, Circulation, 142, e214, 10.1161/CIR.0000000000000905 · DOI
- Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
- Torp-Pedersen, 1999, Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group, N Engl J Med, 341, 857, 10.1056/NEJM199909163411201 · DOI
- Ellenbogen, 1996, Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study, J Am Coll Cardiol, 28, 130, 10.1016/0735-1097(96)00121-0 · DOI
- Stambler, 1996, Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators, Circulation, 94, 1613, 10.1161/01.CIR.94.7.1613 · DOI
- Vardas, 2000, Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study, Chest, 117, 1538, 10.1378/chest.117.6.1538 · DOI
- Kochiadakis, 1998, Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion, Cardiovasc Drugs Ther, 12, 75, 10.1023/A:1007714203984 · DOI
- Stambler, 1997, Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy, Circulation, 96, 4298, 10.1161/01.CIR.96.12.4298 · DOI · Paper page
- Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
- Neefs, 2017, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 231, 155, 10.1016/j.ijcard.2016.12.029 · DOI · Paper page
- Kowey, 2010, Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial, JAMA, 304, 2363, 10.1001/jama.2010.1735 · DOI · Paper page
- Gencer, 2021, Effect of long-term marine -3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis, Circulation, 144, 1981, 10.1161/CIRCULATIONAHA.121.055654 · DOI · Paper page
- Andrade, 2021, Cryoablation or drug therapy for initial treatment of atrial fibrillation, N Engl J Med, 384, 305, 10.1056/NEJMoa2029980 · DOI
- Pérez, 2009, Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis, Circ Arrhythm Electrophysiol, 2, 393, 10.1161/CIRCEP.109.871665 · DOI
- Disertori, 2011, Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial, Am Heart J, 162, 382, 10.1016/j.ahj.2011.05.008 · DOI
- Senoo, 2014, Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation, Circ J, 78, 1121, 10.1253/circj.CJ-13-1272 · DOI
- Yang, 2021, Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: a report from the Chinese Atrial Fibrillation Registry study, J Cardiovasc Electrophysiol, 32, 333, 10.1111/jce.14826 · DOI
- Holmqvist, 2015, Heart rate is associated with progression of atrial fibrillation, independent of rhythm, Heart, 101, 894, 10.1136/heartjnl-2014-307043 · DOI
- January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, 64, e1, 10.1016/j.jacc.2014.03.022 · DOI · Paper page
- Mark, 2019, Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1275, 10.1001/jama.2019.0692 · DOI
- Miura, 2020, Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation, Am Heart J, 222, 83, 10.1016/j.ahj.2020.01.011 · DOI
- Willems, 2022, Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial, Eur Heart J, 43, 1219, 10.1093/eurheartj/ehab593 · DOI
- Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
- Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
- Chew, 2022, Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation, Heart Rhythm O2, 3, 23, 10.1016/j.hroo.2021.11.012 · DOI
- Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406 · DOI
- Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
- Di Biase, 2010, Left atrial appendage: an underrecognized trigger site of atrial fibrillation, Circulation, 122, 109, 10.1161/CIRCULATIONAHA.109.928903 · DOI
- Calkins, 2017, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Heart Rhythm, 14, e275, 10.1016/j.hrthm.2017.05.012 · DOI
- Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
- Calkins, 2009, Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses, Circ Arrhythm Electrophysiol, 2, 349, 10.1161/CIRCEP.108.824789 · DOI · Paper page
- Blomström-Lundqvist, 2019, Effect of Catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial, JAMA, 321, 1059, 10.1001/jama.2019.0335 · DOI
- Packer, 2013, Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial, J Am Coll Cardiol, 61, 1713, 10.1016/j.jacc.2012.11.064 · DOI
- Jais, 2008, Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study, Circulation, 118, 2498, 10.1161/CIRCULATIONAHA.108.772582 · DOI
- Reynolds, 2018, A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial, J Am Coll Cardiol EP, 4, 580
- Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
- Steinberg, 2015, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial, Eur Heart J, 36, 288, 10.1093/eurheartj/ehu359 · DOI
- Al-Khatib, 2013, Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial, Eur Heart J, 34, 2464, 10.1093/eurheartj/eht135 · DOI
- Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
- Piccini, 2012, Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation, Circulation, 126, 2200, 10.1161/CIRCULATIONAHA.112.109330 · DOI
- Calkins, 2017, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Heart Rhythm, 14, e275, 10.1016/j.hrthm.2017.05.012 · DOI
- Campbell, 2020, Sex-based differences in procedural complications associated with atrial fibrillation catheter ablation: a systematic review and meta-analysis, J Cardiovasc Electrophysiol, 31, 3176, 10.1111/jce.14758 · DOI
- Russo, 2021, Association between sex and treatment outcomes of atrial fibrillation ablation versus drug therapy: results from the CABANA trial, Circulation, 143, 661, 10.1161/CIRCULATIONAHA.120.051558 · DOI
- Noseworthy, 2015, Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation, J Am Heart Assoc, 4
- Santhanakrishnan, 2016, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction, Circulation, 133, 484, 10.1161/CIRCULATIONAHA.115.018614 · DOI
- Rillig, 2021, Early rhythm control therapy in patients with atrial fibrillation and heart failure, Circulation, 144, 845, 10.1161/CIRCULATIONAHA.121.056323 · DOI
- Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406 · DOI
- MacDonald, 2011, Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial, Heart, 97, 740, 10.1136/hrt.2010.207340 · DOI
- Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
- Parkash, 2022, Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial, Circulation, 145, 1693, 10.1161/CIRCULATIONAHA.121.057095 · DOI
- Turagam, 2019, Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials, Ann Intern Med, 170, 41, 10.7326/M18-0992 · DOI
- Packer, 2021, Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial, Circulation, 143, 1377, 10.1161/CIRCULATIONAHA.120.050991 · DOI
- Khand, 2003, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, J Am Coll Cardiol, 42, 1944, 10.1016/j.jacc.2003.07.020 · DOI · Paper page
- Kotecha, 2020, Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial, JAMA, 324, 2497, 10.1001/jama.2020.23138 · DOI
- Clemo, 1998, Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias, Am J Cardiol, 81, 594, 10.1016/S0002-9149(97)00962-4 · DOI
- Delle Karth, 2001, Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias, Crit Care Med, 29, 1149, 10.1097/00003246-200106000-00011 · DOI
- Brignole, 1998, Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study, Circulation, 98, 953, 10.1161/01.CIR.98.10.953 · DOI
- Kay, 1998, The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators, J Interv Card Electrophysiol, 2, 121, 10.1023/A:1009795330454 · DOI
- Weerasooriya, 2003, The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT), J Am Coll Cardiol, 41, 1697, 10.1016/S0735-1097(03)00338-3 · DOI
- Nerheim, 2004, Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia, Circulation, 110, 247, 10.1161/01.CIR.0000135472.28234.CC · DOI
- Roy, 2008, Rhythm control versus rate control for atrial fibrillation and heart failure, N Engl J Med, 358, 2667, 10.1056/NEJMoa0708789 · DOI · Paper page
- Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
200 of 246 shown
Cited by
Sorted by citations
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.009 · Cited by 668
Self-citation2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K., Evanovich, L., Ferrari, V. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.014 · Cited by 425
Self-citationMaddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.013 · Cited by 294
Drazner, M. H., Bozkurt, B., Cooper, L. T., Aggarwal, N. R., Basso, C., Bhave, N. M., Caforio, A. L. P., Ferreira, V. M., Heidecker, B., Kontorovich, A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.080 · Cited by 286
Metadata
- Authors
- Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., Linta, K. T., Marcus, G. M., McCarthy, P. M., Patel, N., Patton, K. K., Perez, M. V., Piccini, J. P., Russo, A. M., Sanders, P., Streur, M. M., Thomas, K. L., Times, S., Tisdale, J. E., Valente, A. M., Van Wagoner, D. R., Krahn, A. D., Andrade, J. G., Beavers, C. J., Bischoff, J. M., Bunch, T. J., Campbell, K. B., Chen, L. Y., Dharia, R., Dorsch, M. P., Gerstenfeld, E. P., Jones, A. E., Kaluzna, S. D., Masha, L., Nault, I., Noseworthy, P. A., Pellegrini, C. N., Tzeis, S. E., Volgman, A. S., & Zeitler, E. P.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University of Health Sciences and Pharmacy (US)
- Boston University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Temple University Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Wisconsin–Madison (US)
- University of Louisville (US)
- Denver VA Medical Center (US)
- Stanford Medicine (US)
- Columbia University Irving Medical Center (US)
- University of Arizona (US)
- West Virginia University (US)
- Mayo Clinic (US)
- University of California, San Francisco (US)
- Northwestern Medicine (US)
- University of Washington (US)
- Stanford University (US)
- Duke University (US)
- Royal Adelaide Hospital (AU)
- American College of Cardiology (US)
- Indiana University School of Medicine (US)
- Brigham and Women's Hospital (US)
- ORCID
- Joglar, José A.
- Chung, Mina K.
- Armbruster, Anastasia L.
- Benjamin, Emelia J.
- Chyou, Janice Y.
- Cronin, Edmond M.
- Deswal, Anita
- Eckhardt, Lee L.
- Goldberger, Zachary D.
- Gopinathannair, Rakesh
- Hess, Paul L.
- Hlatky, Mark
- Ibeh, Chinwe
- Indik, Julia H.
- Kido, Kazuhiko
- Kusumoto, Fred
- Link, Mark S.
- Marcus, Gregory M.
- McCarthy, Patrick M.
- Patel, Nimesh
- Patton, Kristen K.
- Perez, Marco V.
- Piccini, Jonathan P.
- Russo, Andrea M.
- Sanders, Prashanthan
- Streur, Megan M.
- Thomas, Kevin L.
- Tisdale, James E.
- Valente, Anne Marie
- Krahn, Andrew D.
- Andrade, Jason G.
- Beavers, Craig J.
- Bunch, T. Jared
- Campbell, Kristen Bova
- Chen, Lin Yee
- Dharia, Robin
- Dorsch, Michael P.
- Jones, Aubrey E.
- Kaluzna, Stephanie Dwyer
- Masha, Luke
- Nault, Isabelle
- Noseworthy, Peter A.
- Pellegrini, Cara N.
- Tzeis, Stylianos E.
- Volgman, Annabelle Santos
- Zeitler, Emily P.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 83
- Issue
- 1
- Pages
- 109-279
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC11104284
- OpenAlex
- W4389165660
- Semantic Scholar
- 6b9e178eb1680000a7b88c27e8b90f736019ac3f
- Cited by
- 933
- References
- 1,396
- Citations by year
- 2026: 383 · 2025: 336 · 2024: 213
- FWCI
- 183.62
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- U.S. Department of Veterans Affairs (IK6 BX006185)
- National Heart, Lung, and Blood Institute (R01HL158071, P01HL158502)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- atrial fibrillation, diagnosis, management, thromboembolic risk assessment, anticoagulation, left atrial appendage closure, catheter ablation, surgical ablation, risk factor control, atrial fibrillation prevention, cardiac arrhythmias
- MeSH terms
- American Heart Association, Atrial Fibrillation, Cardiology, Humans, Risk Factors, Thromboembolism, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
